UM Brain Cancer Vaccine: Ferritin FIT for Glioblastoma
Discover University of Macau's revolutionary ferritin-based in situ vaccine for glioblastoma, achieving 50%+ survival in models via meningeal lymphatic delivery.
No reviews yet. Be the first to rate Zhen!
Professor Zhen Yuan is a full professor in the Faculty of Health Sciences at the University of Macau and Head of the Centre for Cognitive and Brain Sciences. He earned his DEng in Mechanical Engineering (Biomedical Direction) from the University of Science and Technology of China in 2002, following an MEng from the Chinese Academy of Mechanical Sciences and a BEng from Henan University of Science and Technology. His postdoctoral fellowships include positions in biomedical engineering at the University of Florida (2005), physics at Clemson University (2004), and bioengineering at the National University of Singapore (2002). Prior to joining the University of Macau in 2013 as an assistant professor, he held roles as research assistant professor at the University of Florida and clinical assistant professor at Arizona State University.
Professor Yuan’s research focuses on neuroimaging and brain connectome, functional near-infrared spectroscopy (fNIRS), brain disorders, cognitive neuroscience, and brain intervention techniques including ultrasound stimulation, photomodulation, TMS, and tDCS. He has received awards including the 2016 Award for 10 Outstanding Research in Optics and the 2017 FHS Best Teacher Award in Research. His career appointments at the University of Macau include promotion to associate professor in 2017 and full professor in 2021, along with serving as Associate Director of the Institute of Collaborative Innovation since 2023. He maintains professional affiliations as a senior member of SPIE and OSA, and serves on editorial boards including as senior associate editor of BMC Medical Imaging and associate editor of Frontiers in Human Neuroscience.
Discover University of Macau's revolutionary ferritin-based in situ vaccine for glioblastoma, achieving 50%+ survival in models via meningeal lymphatic delivery.